Windtree Therapeutics, Inc. Gross Margin

Gross Margin of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending December 30, 2019 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by -100.0%
  • Annual Gross Margin for 2019 was 100.0% (a 0.0% decrease from previous year)
  • Annual Gross Margin for 2018 was 100.0% (a 0.0% decrease from previous year)
  • Annual Gross Margin for 2017 was 100.0% (a 0.0% decrease from previous year)
  • Twelve month Gross Margin ending December 30, 2019 was 100.0% (a 0.0% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by 0.0% year-over-year
Trailing Gross Margin for the last four month:
30 Dec '19 29 Jun '19 30 Mar '19 30 Dec '18
100.0% 100.0% 100.0% 100.0%
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Windtree Therapeutics, Inc.

Most recent Gross Marginof WINT including historical data for past 10 years.

Interactive Chart of Gross Margin of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 0.0% 100.0% 100.0% 100.0%
2018 100.0% 100.0% 100.0% 100.0% 100.0%
2017 100.0% 100.0% 100.0% 100.0% 100.0%
2016 100.0% 100.0% 100.0% 100.0% 100.0%
2015 100.0% 100.0% 100.0% -386.39% 5.88%
2014 23.82% 51.23% 33.12% -2419.35% 5.78%
2013 100.0% 100.0% 100.0% 100.0% -33.25%
2012 100.0%
2011 100.0% 100.0% 100.0%

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.